EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR–Cas response

Gianna Stella, Linzhi Ye, Sean F Brady, Luciano Marraffini iD

Nucleic Acids Research · 2025

DOI: 10.1093/nar/gkaf1363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Gianna Stella und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Bacteriology, The Rockefeller University, New York, NY 10065, United States. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Phosphoric Monoester Hydrolases, CRISPR-Associated Proteins, Bacterial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIGMS NIH HHS, Howard Hughes Medical Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas (CRISPR-associated) systems provide adaptive immunity against phage infection in prokaryotes using an RNA-guided complex that recognizes complementary foreign nucleic acids. Different types of CRISPR–Cas systems have been identified that differ in their mechanism of defense. Upon infection, type III CRISPR–Cas systems employ the Cas10 complex to find phage transcripts and synthesize cyclic oligo-adenylate (cOA) messengers. These ligands bind and activate CARF immune effectors that cause cell toxicity to prevent the completion of the viral lytic cycle. Here, we investigated two proteins containing an N-terminal haloacid dehalogenase (HAD) phosphatase domain followed by four predicted transmembrane helices and a C-terminal CARF domain. We named these proteins Chp for CRISPR-associated HAD phosphatase. We show that, in vivo, Chp localizes to the bacterial membrane and that its activation induces a growth arrest, leads to a depletion of ATP and IMP, and prevents phage propagation during the type III CRISPR–Cas response. In vitro, the CARF domain of Chp binds cyclic tetra-adenylates and the HAD phosphatase domain dephosphorylates dATP, ATP, and IMP. Our findings extend the range of molecular mechanisms employed by CARF effectors to defend prokaryotes against phage infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsPhosphoric Monoester HydrolasesCRISPR-Associated ProteinsBacterial ProteinsProtein DomainsAdenosine TriphosphateEscherichia coliAdenine Nucleotides

Substanzen

Phosphoric Monoester HydrolasesAdenosine TriphosphateAdenine NucleotidesCRISPR-Associated ProteinsBacterial Proteins

Autor:innen und Institutionen

  • Laboratory of Bacteriology, The Rockefeller University, New York, NY 10065, United States.
  • Tri-Institutional PhD Program in Chemical Biology, Weill Cornell Medical College, Rockefeller University and Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
  • Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, NY 10065, United States.
  • Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, United States.

ORCID-Profile: Luciano Marraffini

Förderung

  • NIH HHS
  • NIGMS NIH HHS
  • Howard Hughes Medical Institute
  • NIH
  • HHMI

Zitieren

APA

Stella, G., Ye, L., Brady, S. F., & Marraffini, L. (2025). CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR–Cas response. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1363

Vancouver

Stella G, Ye L, Brady SF, Marraffini L. CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR–Cas response. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf1363

BibTeX
@article{Stella2025,
  author = {Stella, Gianna and Ye, Linzhi and Brady, Sean F and Marraffini, Luciano},
  title = {CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR–Cas response},
  journal = {Nucleic Acids Research},
  year = {2025},
  doi = {10.1093/nar/gkaf1363}
}
Kostenlos starten →